Viatris Inc. (VTRS)
NASDAQ: VTRS · Real-Time Price · USD
8.68
-0.16 (-1.81%)
Mar 28, 2025, 4:00 PM EDT - Market closed

Company Description

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.

It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars.

It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health.

In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions.

It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies.

The company sells its products under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands.

It has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin.

Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Viatris Inc.
Viatris logo
Country United States
Founded 1961
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 32,000
CEO Scott Smith

Contact Details

Address:
Robert J. Coury Global Center, 1000 Mylan Boulevard
Canonsburg, Pennsylvania 15317
United States
Phone 724 514 1800
Website viatris.com

Stock Details

Ticker Symbol VTRS
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001792044
CUSIP Number 92556V106
ISIN Number US92556V1061
Employer ID 83-4364296
SIC Code 2834

Key Executives

Name Position
Scott Andrew Smith Ph.D. Chief Executive Officer and Director
Brian S. Roman Chief Legal Officer
Theodora Mistras Chief Financial Officer
Paul B. Campbell Chief Accounting Officer, Senior Vice President and Corporate Controller
Ramkumar V. Rayapureddy Chief Information Officer
Andrew Enrietti Chief People Officer
Menassie Taddese M.B.A. President of Emerging Markets
Derek Glover Chief Quality Officer
Lara Ramsburg Chief Corporate Affairs Officer
Dr. Jeffrey Nau MMS, Ph.D. President of Viatris Eye Care Division

Latest SEC Filings

Date Type Title
Feb 27, 2025 10-K Annual Report
Feb 27, 2025 8-K Current Report
Jan 24, 2025 SCHEDULE 13G Filing
Dec 6, 2024 8-K Current Report
Nov 12, 2024 144 Filing
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 10-Q Quarterly Report
Nov 7, 2024 8-K Current Report
Oct 25, 2024 ARS Filing
Oct 25, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material